Literature DB >> 7468740

Safety and effectiveness of concomitant administration of dipivefrin and timolol maleate.

E U Keates, R A Stone.   

Abstract

Dipivefrin, an epinephrine prodromal drug, was used in conjunction with timolol maleate to evaluate the safety and effectiveness of combined therapy. Seventeen patients who had used timolol maleate for at least six months added dipivefrin (Group 1) and seven patients who had used dipivefrin for at least six months added timolol maleate (Group 2). Intraocular pressure decreased further in both groups. Side effects were most prominent in Group 1.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7468740     DOI: 10.1016/0002-9394(81)90182-3

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  6 in total

1.  Adrenergic and adrenolytic effects on intraocular pressure.

Authors:  S M Drance; G R Douglas; K J Wijsman; M Schulzer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

2.  The efficacy of the combination of l-moprolol and dipivefrin in reducing the intraocular pressure in primary open-angle glaucoma or in ocular hypertension.

Authors:  L Rossetti; P Barbieri; P Velati; E Bujtar; N Orzalesi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-11       Impact factor: 3.117

Review 3.  A risk-benefit assessment of drugs used in the management of glaucoma.

Authors:  T Taniguchi; Y Kitazawa
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

Review 4.  Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects.

Authors:  A M Brooks; W E Gillies
Journal:  Drugs Aging       Date:  1992 May-Jun       Impact factor: 3.923

5.  Long-term drift and timolol therapy: possible role for pulsed therapy.

Authors:  M Batterbury; S P Harding; D Wong
Journal:  Int Ophthalmol       Date:  1992-09       Impact factor: 2.031

6.  A single-blind randomised trial comparing adrenaline 1.0% with dipivalyl epinephrine (propine) 0.1% in the treatment of open-angle glaucoma and ocular hypertension.

Authors:  K B Mills; N A Jacobs
Journal:  Br J Ophthalmol       Date:  1988-06       Impact factor: 4.638

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.